Servier Singapore

Servier Singapore company information, Employees & Contact Information

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities. A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies. -- To report a suspected adverse event with a Servier drug, please report to your health authority or via https://servier.com/en/contact/report-a-side-effect/

Company Details

Employees
13
Address
67 Ubi Avenue 1, Starhub Green #06-09,singapore
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Singapore
Looking for a particular Servier Singapore employee's phone or email?

Servier Singapore Questions

News

Blue March 2025: More determined than ever to combat colorectal cancer - Servier

Blue March 2025: More determined than ever to combat colorectal cancer Servier

Tackling Inequities in Childhood Cancer Through Unique Global Collaboration - Servier

Tackling Inequities in Childhood Cancer Through Unique Global Collaboration Servier

Finally, a day dedicated to therapeutic adherence! - Servier

Finally, a day dedicated to therapeutic adherence! Servier

Servier takes on therapeutic adherence! - Servier

Servier takes on therapeutic adherence! Servier

Integrated annual report 2023/2024 - Servier

Integrated annual report 2023/2024 Servier

Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030 - Servier

Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030 Servier

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide - Yahoo Finance

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide Yahoo Finance

Servier appoints David K. Lee to Executive Committee - Servier

Servier appoints David K. Lee to Executive Committee Servier

Servier and Google Cloud Expand Partnership on using data and AI - Servier

Servier and Google Cloud Expand Partnership on using data and AI Servier

Bio-S: a unique facility in Europe for the clinical manufacture of new biodrugs - Servier

Bio-S: a unique facility in Europe for the clinical manufacture of new biodrugs Servier

GreenScore: A User-Friendly Tool for Assessing the Sustainability of Chemical Processes - ACS Publications

GreenScore: A User-Friendly Tool for Assessing the Sustainability of Chemical Processes ACS Publications

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals - Oncodaily

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals Oncodaily

Servier and Black Diamond Therapeutics Announce Global - GlobeNewswire

Servier and Black Diamond Therapeutics Announce Global GlobeNewswire

7 start-ups hosted - Servier

7 start-ups hosted Servier

Our commitment to oncology - Servier

Our commitment to oncology Servier

Servier Executive Committee appointments - Servier

Servier Executive Committee appointments Servier

See our bases throughout the world - Servier

See our bases throughout the world Servier

The age of augmented research - Servier

The age of augmented research Servier

Parkinson’s Disease: New Collaboration with Aitia - Servier

Parkinson’s Disease: New Collaboration with Aitia Servier

Neuroscience: new research partnership for Servier - Servier

Neuroscience: new research partnership for Servier Servier

Celebrating SRIMC: A Decade of Innovation in Chemistry - Servier

Celebrating SRIMC: A Decade of Innovation in Chemistry Servier

Our ambition for 2030 - Servier

Our ambition for 2030 Servier

Insights, the magazine that deciphers the pharmaceutical industry - Servier

Insights, the magazine that deciphers the pharmaceutical industry Servier

Cardiology: Gaining perspective on therapeutic adherence - Servier

Cardiology: Gaining perspective on therapeutic adherence Servier

All our latest news - Servier

All our latest news Servier

Servier at ASH meeting to present new data in hematology research - Servier

Servier at ASH meeting to present new data in hematology research Servier

Patient associations’ perception of pharmaceutical companies: Servier is making progress! - Servier

Patient associations’ perception of pharmaceutical companies: Servier is making progress! Servier

Nicolas Lévy joins Servier as Chief Scientist Rare Diseases - Servier

Nicolas Lévy joins Servier as Chief Scientist Rare Diseases Servier

Nicolas Garnier joins Servier as Chief Patient Officer - Servier

Nicolas Garnier joins Servier as Chief Patient Officer Servier

The Servier Saclay R&D Patient Board: A podcast series - Servier

The Servier Saclay R&D Patient Board: A podcast series Servier

She Is Servier program launches in Asia - Servier

She Is Servier program launches in Asia Servier

Servier is Top Employer Europe for the 3rd consecutive year! - Servier

Servier is Top Employer Europe for the 3rd consecutive year! Servier

Servier reveals a new visual identity - Servier

Servier reveals a new visual identity Servier

Changes to the Executive Committee of Servier Group - Servier

Changes to the Executive Committee of Servier Group Servier

PRISM BioLab, a new partner for Servier in immuno-oncology - Servier

PRISM BioLab, a new partner for Servier in immuno-oncology Servier

New managerial practices to foster employee engagement - Servier

New managerial practices to foster employee engagement Servier

The Research and Development Institute in Paris-Saclay - Servier

The Research and Development Institute in Paris-Saclay Servier

Appointment of Walid S. Kamoun, PhD. MSc., Global Head of Servier R&D Oncology - Servier

Appointment of Walid S. Kamoun, PhD. MSc., Global Head of Servier R&D Oncology Servier

First review for PROMETCO, Servier’s real-world study - Servier

First review for PROMETCO, Servier’s real-world study Servier

Servier on the front line of cardiovascular disease prevention and therapeutic adherence - Servier

Servier on the front line of cardiovascular disease prevention and therapeutic adherence Servier

Discover in video the commitment of Servier in oncology - Servier

Discover in video the commitment of Servier in oncology Servier

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma - PR Newswire

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma PR Newswire

Comprehensive Characterization of IgG2 Disulfide Isoforms Using Native Cation Exchange Chromatography-Mass Spectrometry and Peptide Mapping - ACS Publications

Comprehensive Characterization of IgG2 Disulfide Isoforms Using Native Cation Exchange Chromatography-Mass Spectrometry and Peptide Mapping ACS Publications

Tutorial Videos - Servier Medical Art

Tutorial Videos Servier Medical Art

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI) - PR Newswire

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI) PR Newswire

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder - Yahoo Finance

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder Yahoo Finance

White blood cells Archives - Servier Medical Art

White blood cells Archives Servier Medical Art

European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU - Yahoo Finance

European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU Yahoo Finance

Servier Completes Acquisition of Agios Pharmaceuticals' Oncology Business - PR Newswire

Servier Completes Acquisition of Agios Pharmaceuticals' Oncology Business PR Newswire

Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting - Allogene

Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting Allogene

Servier to Acquire Agios Pharmaceuticals' Oncology Business - PR Newswire

Servier to Acquire Agios Pharmaceuticals' Oncology Business PR Newswire

Servier Completes the Acquisition of Symphogen - PR Newswire

Servier Completes the Acquisition of Symphogen PR Newswire

Drugs and Treatments - Servier Medical Art

Drugs and Treatments Servier Medical Art

Servier unveils its 2030 ambition and reveals a new visual identity - PR Newswire UK

Servier unveils its 2030 ambition and reveals a new visual identity PR Newswire UK

Top Servier Singapore Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant